B7-33 - 10mg

1,800+ Verified Orders!

B7-33 - 10mg

€39,99
€59,99
33% OFF
33% OFF

Third Party Tested

14-Day Money Back Guarantee

Fast Delivery Worldwide

1,800+ Verified Orders!

B7-33 - 10mg

€39,99
€59,99
33% OFF
33% OFF

Third Party Tested

14-Day Money Back Guarantee

Fast Delivery Worldwide

B7-33 is a synthetic peptide analog derived from relaxin-2 that retains antifibrotic effects without estrogenic and cardiovascular effects. It is being investigated for its ability to modulate fibrotic activity in liver, lung, kidney and heart injury.

Parameters
Value
Form
Lyophilized powder
Contents
10 mg
Concentration (test)
Unspecified
Packaging
Glass bottle with sterile cap
Storage
2–8 °C, away from light
Molecular formula
C160H260N52O49
Molecular weight
3674.1 g mol⁻¹
IUPAC name
[B7-33 relaxin-2 peptide chain]
CAS number
Unassigned
Other names
B7-33 relaxin analogue
  • reduction of fibrosis in the liver, lungs and kidneys,
  • antifibrotic effect without estrogenic effects,
  • potential in the treatment of heart failure,
  • reduction of inflammation and oxidative stress,
  • research in fibrotic diseases and TGF-β signaling.

This professional text is for educational and research purposes only. It does not constitute a recommendation for human use.

What is B7-33?

B7-33 is an experimental synthetic peptide derived from relaxin-2, specifically designed to retain its antifibrotic effects without the cardiovascular side effects. Unlike the full hormone relaxin, it does not act through the RXFP1 receptor in the classical sense, but only activates specific downstream pathways.

How does B7-33 work?

It activates MAPK/ERK signaling, thereby inhibiting TGF-β-induced expression of fibrotic genes (e.g., type I collagen, fibronectin). It also reduces alpha-SMA expression in myofibroblasts, thereby preventing epithelial cell transition to a fibroblastic phenotype (EMT).

Effects studied

  • Reduction of liver, lung and kidney fibrosis in preclinical models.
  • Reversal of myofibroblast activity without hormonal stress.
  • Improving heart function in diastolic failure.
  • Reduction of inflammation and oxidative stress in tissues.
  • Decreased expression of profibrotic biomarkers.

Dosage in studies

These data are based on preclinical studies. They are not recommendations for human use.

  • Dose: 0.5–5 mg/kg daily
  • Administration form: intraperitoneal or subcutaneous
  • Frequency: 1× daily
  • Duration: 1–4 weeks (depending on model)

Dosage is for laboratory purposes only. It does not indicate use in humans.

Possible side effects

  • Mild hypotension in case of systemic administration.
  • Transient redness at the injection site.
  • Limited long-term safety data.

Resources

  • Samuel et al., 2017 - "Relaxin Peptides in Fibrosis and Organ Failure"
  • Frontiers in Pharmacology – Antifibrotic properties of B7-33
  • PubMed ID: 28495822

All information is for educational and research purposes only. The product is not approved for human use.

Why Limitless Biochem?

Limitless BioChem is a trusted supplier of research compounds. Our products meet strict quality standards and are compliant with EU requirements. We focus on the safe and reliable supply of peptides and pure compounds intended exclusively for research or collector purposes.

Peptides, Nootropics, Amino acids...

Products tested by an independent laboratory

Exclusively pure compounds without additives

Worldwide delivery

Warning

This product is not intended for human or veterinary use. It is for collection or research purposes only. It cannot be used as food, dietary supplement or medicine! The information provided in the text on this page is for educational purposes only and does not constitute medical or other advice.

You may also be interested in